

ValiRx PLC

07:42 25 Apr 2018

ValiRx receives EU patent grant for prostate cancer drug

ValiRx PLC (LON:VAL) said it has received a patent grant from the EU patent and trademark office for its VAL201 prostate cancer treatment that is currently in clinical trials.

The AIM-listed pharmaceuticals company said in a **statement** that the patent grant represented another major milestone in its commercial strategy, with the VAL201 portfolio having received patents in the US, UK, Japan, and Australia previously.

READ: ValiRx shoots higher, innovation effective at inducing programmed cell death in a wide range of cancers

ValiRx added that VAL201 is currently in a Phase I/II clinical study assessing its safety and tolerability as well as its effect in the treatment of prostate cancer and other solid tumours, with no dose-limiting toxicity or therapeutically-related side effects having been observed.

The group also said VAL201 has met and exceeded predicted safety and tolerability criteria set for the trial, with subjects showing preliminary therapeutic efficacy and significant changes in their prostate-specific antigen levels related to treatment with VAL201.

ValiRx added that pre-clinical studies have also shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone-induced abnormal cell growth in women.

Dr Satu Vainikka, ValiRx chief executive, said: "I am very pleased that VAL201 has received its European Union patent grant, hot on the heels of our receipt of a US patent grant [on 20 March 2018].

She added: "This latest grant now means that ValiRx has substantive patent protection stretching across the globe and I believe it further bolsters the Company's opportunity of securing a partnering deal, particularly in the light of the expansion of the VAL201 trial to more speedily reach VAL201's full therapeutic potential and potential anti-cancer impact".

Price: 0.135

Market Cap: £1.38 m

1 Year Share Price Graph



October 2018 April 2019 October 2019

Share Information

Code: VAL

Listing: AIM

52 week High Low
1.805 0.1201

Sector: Pharma & Biotech

Website: www.valirx.com

Company Synopsis:

ValiRx PLC is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering. We focus on the novel treatments of cancers and associated Biomarkers. Our technologies and products however can also be applied to the other fields as well, such as neurology and inflammatory diseases.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).